Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer

Open Access

Peer-reviewed

Research Article

Paul Toren,

Affiliation The Vancouver Prostate Centre, Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
⨯
Soojin Kim,

Affiliation The Vancouver Prostate Centre, Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
⨯
Fraser Johnson,

Affiliation The Vancouver Prostate Centre, Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
⨯
Amina Zoubeidi

* E-mail: azoubeidi@prostatecentre.com

Affiliation The Vancouver Prostate Centre, Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
⨯

Reader Comments (0)

Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.
Androgens
Is the Subject Area "Androgens" applicable to this article?

Thanks for your feedback.
Signal inhibition
Is the Subject Area "Signal inhibition" applicable to this article?

Thanks for your feedback.
Apoptosis
Is the Subject Area "Apoptosis" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Cell cycle and cell division
Is the Subject Area "Cell cycle and cell division" applicable to this article?

Thanks for your feedback.